Lancet Rheumatology

Article	Citations
Molecular signature-based decision making in the era of targeted therapies for systemic lupus erythematosus	951
Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease	904
Brachial plexopathy: an unusual manifestation of Takayasu arteritis	324
Thrombotic microangiopathy as a presentation of anti-synthetase syndrome	201
A disseminated gonococcal infection with spinal locations	189
Dual JAK and ROCK inhibition with CPL'116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo-controlled, phase 2 trial	133
Research in Brief	133
Reigniting the burnt-out health-care workforce	120
Women in rheumatology in Africa	118
Biological disease-modification in axial spondyloarthritis: insights from MRI	114
Pathways driving tendinopathy and enthesitis: siblings or distant cousins in musculoskeletal medicine?	110
Three-dimensional, in-vitro approaches for modelling soft-tissue joint diseases	104
Can contextual factors improve clarity of the results from clinical trials of low back pain?	87
COVID-19 vaccine-induced T-cell responses in patients with rheumatoid arthritis: preferential induction by ChAdOx1	83
From phenotype to pathophysiology—placing rheumatic diseases in an immunological perspective	76
Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study	72
Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries	70
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial	68
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?	62
Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands	61
Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica due to lumbar disc herniation	58
1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial	58
Interleukin-5 inhibition in eosinophilic granulomatosis with polyangiitis: time for another approach?	56
Early-stage Dupuytren's disease treatment; a promising next step?	54
Juvenile systemic lupus erythematosus presenting as retinal vasculitis	49

The association of outdoor temperature and self-reported Raynaud's phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study	47
Reclassifying ANCA-associated vasculitis: a focus on kidney disease	46
Research in Brief	46
Composite endpoints for Sjögren's Syndrome	45
Immunity after COVID-19 vaccinations in immunocompromised patients with psoriasis	45
Outdoor temperatures and Raynaud's phenomenon in patients with systemic sclerosis	45
Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial	44
Assessing glucocorticoid toxicity: are the measures sensitive enough?	44
Patient-reported outcomes with anifrolumab in patients with systemic lupus erythematosus	44
Preload deficiency as a treatable cause of fatigue and exercise intolerance in SLE	43
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study	43
Sex as a predictor of clinical phenotype and determinant of immune response in IgG4-related disease: a retrospective study of patients fulfilling the American College of Rheumatology–European League A	43
First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: a multicentre, retrospective, propensity weighted cohort study	42
Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus	42
Proof-of-concept studies in axial spondyloarthritis: there are no shortcuts	42
Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis	41
Addition of aerobic physical activity to resistance exercise for hip osteoarthritis (PHOENIX): a randomised comparative effectiveness trial	40
Biosimilars and the era of interchangeability	39
Pain in clinical trials for knee osteoarthritis: estimation of regression to the mean	39
Clinical trial design: time to accelerate the pace of change?	38
Kanon Jatuworapruk: bringing out the enjoyment in life	37
Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a p	36
Clinical hypnosis and pain management in sharp debridement of skin ulcers in immune-mediated inflammatory diseases	35
Additional SARS-CoV-2 vaccine doses: a little is better than none	35
Research in Brief	34
ANCA-associated large and small vessel vasculitis with aorto-pulmonary-renal syndrome	34
Urgent reform needed for homecare medicines services	34
Optimal non-opioid analgesic combinations after total hip arthroplasty – Authors' reply	33
Mental health before and during the pandemic in people with systemic sclerosis	33
IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19	32
Constitutional symptoms of severe childhood-onset polyarteritis nodosa	32
Global access to biological disease-modifying drugs	31
Let's talk about sex in interstitial lung disease	31
Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study	30
Fetal and maternal outcome in the pregnancies of patients with systemic sclerosis and very early diagnosis of systemic sclerosis in France: a prospective study	30
Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial	30
Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in children: a multicentre, retrospective, cohort study	29
Tackling heterogeneity in Sjögren's disease	29
Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies	29
Development of a diagnostic prediction model for giant cell arteritis by sequential application of Southend Giant Cell Arteritis Probability Score and ultrasonography: a prospective multicentre study	28
Who will respond to type I interferon receptor blockade in SLE?	27
Research in Brief	27
COVID-19: is the rush to boost backed by science?	27
The 2024 US election—voting for equitable health care	26
Advancing research and equity through collaboration	26
Pneumococcal vaccine in adults with immune-mediated inflammatory diseases	26
Call for papers: Sex and gender in rheumatology	26
Are we ready for home spirometry for systemic sclerosis-associated ILD?	26
Sex differences of brain oscillatory activity and quantitative sensory testing in people with chronic osteoarthritis pain: a cross-sectional study	26
Suspending methotrexate for 2 weeks after COVID-19 vaccination	26

Correction to Lancet Rheumatol 2025; published online Feb 27. https://doi.org/10.1016/S2665-9913(24)00348-5	25
JIA care under the microscope	25
Enabling and supporting public and patient involvement in arthritis research	25
Explanation for substandard of care comparators in rheumatology randomised trial protocols	25
Better diagnostic tools needed for biopsy-negative giant cell arteritis	25
Digital self-management for back pain in the UK	25
Humoral response following SARS-CoV-2 vaccination: not all immunosuppressants are created equal	25
Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials	24
Development and validation of an OMERACT ultrasound scoring system for the extent of calcium pyrophosphate crystal deposition at the joint level and patient level	24
Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national co	24
Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort	24
Telemedicine: is the new normal fit for purpose?	24
The impact of COVID-19 on care of early inflammatory arthritis in the UK	23
Cranial involvement in giant cell arteritis	23
Pain and wellbeing in young people with arthritis	23
Challenges in the therapeutic management of psoriatic arthritis	23
Intra-articular botulinum toxin A injection for painful base-of-thumb osteoarthritis: a double-blind, randomised, controlled, phase 3 trial (RHIBOT)	23
COP27 Climate Change Conference: urgent action needed for Africa and the world	23
Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study	23
Sex and gender impact on achievement of remission in people with rheumatoid arthritis in Switzerland: a cohort study	22
Beneficial side-effects of colchicine for patients with gout	22
Sex-related differences in health-care use in adult patients with inflammatory arthritis in Ontario, Canada: a population-based cohort study	22
Jean Liew: from Bronte scholar to social media influencer	22
Microscopic polyangiitis presenting with retinal frosted branch angiitis	22
For SLE activity and glucocorticoids: aim low	22
Polychondritis in a child	22
Penélope Palominos: rheumatology by sight and touch	22
Refining strategies for biological and targeted synthetic DMARD initiation in rheumatoid arthritis – Authors' reply	22
Reconciling immunotherapy and autoimmunity: not for the faint of heart	22
Vascular Ehlers-Danlos syndrome: a heritable condition with potentially fatal consequences	21
Treatment modalities of marginal zone lymphoma and overall survival, haematological response, and underlying Sjögren's disease activity: a multicentre, retrospective, observational study	21
Gout in central Asia: a few things make a big difference	20
Factors associated with resolution of ultrasound subclinical synovitis in anti-CCP-positive individuals with musculoskeletal symptoms: a UK prospective cohort study	20
Serum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: a retrospective cohort study	20
Coronary polyarteritis nodosa	20
Effectiveness of pneumococcal vaccination in adults with common immune-mediated inflammatory diseases in the UK: a case–control study	20
Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses	20
How long do revised and multiply revised hip replacements last? A retrospective observational study of the National Joint Registry	20
David Liew: where communication meets medicine	19
Ustekinumab with or without methotrexate for psoriatic arthritis?	19
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial	19
Research in Brief	19
Systemic sclerosis and pregnancy: advancing prospective evidence for risk stratification and postpartum care	19
Effectiveness of a fourth mRNA dose among individuals with systemic autoimmune rheumatic diseases during the Omicron era	18
Research in Brief	18
Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica due to lumbar disc herniation – Authors' reply	18
Rheumatology congresses post COVID-19: we cannot regress	18
Role of plasma exchange in ANCA-associated vasculitis – Authors' reply	18
Correction to Lancet Rheumatol 2023; 5: e461–73	18
DAVIX: a vascular outcome measure in systemic sclerosis	18
Thank you to our peer reviewers in 2021	17
Distinct immune response to CoronaVac in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic disease	17
Composite endpoints for Sjögren's Syndrome – Authors' reply	17
Prevention of psoriatic arthritis: the next frontier	16
Advancing predictive accuracy for shoulder replacement surgery	16
Coronary polyarteritis nodosa in a young adult	16
Cognitive impairment in individuals with rheumatic diseases: the role of systemic inflammation, immunomodulatory medications, and comorbidities	15
Prize trends in rheumatology: the Gender Award Gap	15
Digital remote monitoring in rheumatology: using health economics to support wider adoption	15
Vasculitis management remains a challenge during pregnancy	15
Association of nirmatrelvir–ritonavir with post-acute sequelae and mortality among patients who are immunocompromised with COVID-19 in Hong Kong: a retrospective cohort study	15
Occupational therapist-led versus rheumatologist-led care in people with hand osteoarthritis in Norway: an open-label, multicentre, randomised controlled, non-inferiority trial	15
Substantiation of trophoblast transport of maternal anti-SSA/Ro autoantibodies in fetuses with rapidly progressive cardiac injury: implications for neonatal Fc receptor blockade	15
Time to revisit the therapeutic benefits of exercise for osteoarthritis?	15
Global, regional, and national burden of other musculoskeletal disorders, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	14
Diffuse alveolar haemorrhage during pregnancy in systemic lupus erythematosus	14
Titilola (Lola) Falasinnu: looking out for the overlooked	14
Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study	14
Research in Brief	14
Industry involvement in rheumatology consensus-based recommendations: a systematic review	14
Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study	14
Research in Brief	14
Research in Brief	14
Interosseous tendon inflammation in the hands of patients with clinically suspect arthralgia: analysis of MRI data from a prospective cohort study	14
Susac syndrome: challenges of interpreting treatment data in a rare disease	13
Cardiovascular risk in gout: time for action	13
Correction to Lancet Rheumatol 2022; 4: e853–63	13
Rheumatic cognitive impairment: a new clinical entity?	13
Palliative care in patients with rheumatic diseases	13
Vasculitis: the promising road ahead	13

Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a	13
The influence of safety warnings on the prescribing of JAK inhibitors	13
Psoriatic arthritis: strategy shaping treatment	13
Research in Brief	13
Correction to Lancet Rheumatol 2022; 4: e177–87	13
The same genotype gives rise to a spectrum of disorders	13
Debate over interventional procedures for chronic spine pain	13
Cellular responses to SARS-CoV-2 vaccination after B-cell depletion: conflicting results from studies – Authors' reply	12
Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab	12
Beyond very early systemic sclerosis: deciphering pre‑scleroderma and its trajectories to open new avenues for preventive medicine	12
Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised contr	12
Getting better at quantifying the toxicity of glucocorticoids	12
CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series	12
Time to talk to adults with rheumatic diseases about herpes zoster vaccination	12
Calcium pyrophosphate deposition disease	12
Predictors of pregnancy outcomes in SLE	12
Disease-associated brain activation predicts clinical response to TNF inhibition in rheumatoid arthritis (PreCePra): a randomised, multicentre, double-blind, placebo-controlled phase 3 study	12
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study	12
Michael Barrett: navigating hostile terrain	12
Predictors of pregnancy outcomes in SLE	11
Moderators of the effect of therapeutic exercise for knee and hip osteoarthritis: a systematic review and individual participant data meta-analysis	11
Safety of CAR T-cell therapy for cancer in pre-existing autoimmune or inflammatory disease: a retrospective comparative cohort study	11
Preclinical or subclinical rheumatoid arthritis-associated interstitial lung disease: misleading terms with potentially deleterious consequences	11
Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, obse	11
Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study	11
Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial	11
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial	10
Narendra Kumar Bagri: taking paediatric rheumatology in India to new heights	10
Differentiating biologics to prevent psoriatic arthritis in patients with psoriasis	10
Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study	10
Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with refractory systemic lupus erythematosus – Authors' reply	10
Promise and challenges of mesenchymal stromal cell therapy in severe SLE	10
Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational study	10
Aspirin desensitisation in pregnant individuals with autoimmune disease	10
Modelling allopurinol-induced severe adverse cutaneous reactions	10
Self-management of gout using a mobile app	9
Identifying key health system components associated with improved outcomes to inform the re-configuration of services for adults with rare autoimmune rheumatic diseases: a mixed-methods study	9
Long COVID in inflammatory rheumatic diseases—what's in a name?	9
Immunosuppression and SARS-CoV-2 breakthrough infections	9
Debashish Danda	9
Contesting the BACPAP consortium's consensus – Authors' reply	9
Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	9
Inclusion of pregnant populations in clinical trials in China: the ethical considerations	9
Research in Brief	9
Including refractory systemic sclerosis-associated GAVE in research agendas	9
Coronary polyarteritis nodosa in a young adult – Authors' reply	9
Kimberly Templeton: creative change maker	9
Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease	9
Challenges of designing and conducting cohort studies and clinical trials in populations of pregnant people	9
Correction to Lancet Rheumatol 2022; 4: e262–73	9
Synovial tissue for personalised medicine in rheumatoid arthritis: hype or hope?	9
Research in Brief	9
Dual JAK and ROCK inhibition and comorbidities in rheumatoid arthritis	9
Correction to Lancet Rheumatol 2021; 3: e789–97	9
When the game changes: efficacy of rituximab in systemic sclerosis	8
Barriers to CAR T-cell therapy in rheumatology	8
Botulinum toxin A: a short-term treatment option for base-of-thumb osteoarthritis?	8
Irish experiences of parenting with early inflammatory arthritis: a qualitative study	8
Research in Brief	8
Risk-based stratified primary care for common musculoskeletal pain presentations (STarT MSK): a cluster-randomised, controlled trial	8
Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study	8
Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study	8
Precision medicine in rheumatoid arthritis: unravelling sex-driven differences in response to treatment	8
Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study	8
Improvement of a giant cell arteritis prediction model	8
Hip-focused physical therapy versus spine-focused physical therapy for older adults with chronic low back pain at risk for mobility decline (MASH): a multicentre, single-masked, randomised controlled	8
Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial	8
Large vessel giant cell arteritis	7
Immunosuppression, nirmatrelvir–ritonavir, and post-COVID condition	7
A fluffy white retinal lesion in a woman with spondyloarthritis treated with tofacitinib	7
From whole-brain metrics to circuit-specific precision: advancing fMRI biomarkers for TNF inhibitor response in rheumatoid arthritis	7
Correction to Lancet Rheumatol 2025; 7: e747	7
Fatigue in patients with ANCA-associated vasculitis: is avacopan the answer?	7
A glucocorticoid-free era for polymyalgia rheumatica: are we on the brink of change?	7
Reasoning large language models in rheumatology: a call for responsible action	7
Diagnostic, research, and real-life effect of the 2023 EULAR−ACR classification criteria for antiphospholipid syndrome	7
Research in Brief	7
The impact of sex and anti-topoisomerase I antibodies in systemic sclerosis	7
Subclinical synovitis: let's discuss prognosis before treatment	6
Back pain: a target for reducing hospital admissions?	6
A new era of non-opioid analgesics?	6
Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City	6
Refining strategies for biological and targeted synthetic DMARD initiation in rheumatoid arthritis	6
Research in Brief	6
Biosimilar tocilizumab—better access and lower cost?	6
Is faecal microbiota transplantation ready for prime time in systemic sclerosis?	6
Correction to Lancet Rheumatol 2025; published online Oct 15. https://doi.org/10.1016/S2665-9913(25)00248-6	5
Time to listen to women about their pain	5
Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive de	5
ChatSLE: consulting ChatGPT-4 for 100 frequently asked lupus questions	5
Why is progressive ILD in systemic sclerosis so difficult to predict?	5
Investigating sex differences in T regulatory cells from cisgender and transgender healthy individuals and patients with autoimmune inflammatory disease: a cross-sectional study	5
Pachydermodactyly: mimic of arthritis in a young man	5
Sustained DMARD-free remission in subgroups of patients with rheumatoid arthritis: an analysis of two prospective cohorts with early arthritis	5
Socioeconomic vulnerability and rheumatoid arthritis in the Philippines	5